Research ArticleOncology

Pretreatment 18F-FDG PET/CT Radiomics Predict Local Recurrence in Patients Treated with Stereotactic Body Radiotherapy for Early-Stage Non–Small Cell Lung Cancer: A Multicentric Study

Gurvan Dissaux, Dimitris Visvikis, Ronrick Da-ano, Olivier Pradier, Enrique Chajon, Isabelle Barillot, Loig Duvergé, Ingrid Masson, Ronan Abgral, Maria-Joao Santiago Ribeiro, Anne Devillers, Amandine Pallardy, Vincent Fleury, Marc-André Mahé, Renaud De Crevoisier, Mathieu Hatt and Ulrike Schick
Journal of Nuclear Medicine June 2020, 61 (6) 814-820; DOI: https://doi.org/10.2967/jnumed.119.228106

Article Figures & Data

Figures

  • FIGURE 1.
    FIGURE 1.

    Images obtained at Brest (Biograph; Siemens) (A), Rennes (Discovery ST; GE Healthcare) (B), Tours (Ingenuity; Philips) (C), and Nantes (Biograph) (D), with semiautomatically fuzzy locally adaptive Bayesian segmentation on corrected PET and corresponding manual gross-tumor volume segmentation on CT with lung window setting.

  • FIGURE 2.
    FIGURE 2.

    (A) Receiver-operating-characteristic curve analysis for prediction of local control according to PET IC2 and PET strength in training cohort. (B) Kaplan–Meier curve of local control based on radiomic signature PET IC2 and PET strength in training cohort. AUC = area under curve.

  • FIGURE 3.
    FIGURE 3.

    Receiver-operating-characteristic curve analysis for prediction of local control according to model combining PET IC2 and CT flatness in training cohort. AUC = area under curve.

  • FIGURE 4.
    FIGURE 4.

    (A) Receiver-operating-characteristic curve analysis for prediction of local control according to model combining PET IC2 and PET strength in testing cohort. (B) Kaplan–Meier curve of local control based on radiomic model combining PET IC2 and PET strength in testing cohort. AUC = area under curve.

Tables

  • TABLE 1

    Patient and Tumor Characteristics

    CharacteristicTraining set (n = 64)Testing set (n = 23)P
    Median age (y)72 (range, 45–87)69 (range, 52–85)0.589
    Median tumor volume (cm3)133.3 (range, 8.3–946.9)149.7 (range, 5.7–987.2)0.946
    T stage (n)
     T113 (20.3%)4 (17.4%)0.864
     T251 (79.7%)19 (82.6%)
    Sex (n)
     Male48 (75%)19 (82.6%)0.821
     Female16 (25%)4 (17.4%)
    Histology (n)
     Adenocarcinoma25 (39%)12 (52.2%)0.742
     Other histologies9 (14%)5 (21.7%)
     Unknown30 (47%)6 (26.1%)
    WHO performance status (n)
     0–149 (76.6%)22 (95.6%)0.435
     >115 (23.4%)1 (4.4%)
    Tumor location (n)
     Peripheral55 (85.9%)21 (91.3%)0.558
     Central9 (14.1%)2 (8.7%)
    BED10 (n)
     <150 Gy41 (64%)17 (73.9%)0.599
     >150 Gy23 (36%)6 (26.1%)
    Median SUVmax7.76 (range, 2.5–36.2)7.79 (range, 2.5–18.6)0.538

    • WHO = World Health Organization; BED10 = biologically equivalent dose.

  • TABLE 2

    Uni- and Multivariate Analysis for Local Control in Training Set

    UnivariateMultivariate
    CharacteristicHR95% CIPHR95% CIP
    Age (<72 vs. ≥72 y)——0.975
    Tumor volume (>132 vs. ≤132 cm3)——0.059
    TNM (T2 vs. T1)60.1–4050.078
    Sex (male vs. female)30.3–290.251
    Histopathologic type (others vs. ADK)30.4–210.297
    WHO performance status (≤1 vs. 2)——0.420
    Localization (peripheral vs. central)——0.793
    BED10 (>151.2 vs. ≤151.2 Gy)——0.016
    Radiomic signature
     PET signature (IC2 and strength)——<0.00130.752.56–369.110.007
     PET/CT signature (PET IC2 and CT flatness)——<0.00137.53.13–448.610.004

    • ADK = adenocarcinoma; WHO = World Health Organization; BED10 = biologically equivalent dose.

Additional Files

Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools
Bookmark this article

Jump to section

Keywords